Bevacizumab (Avatin) for Diabetic Macular Edema in Previouly Vitrectomized Eye

Purpoe To report the viual acuity (VA) and foveal thickne (FT) change after intravitreal bevacizumab for diabetic macular edema (DME) in previouly vitrectomized eye. Deign Retropective, noncomparative, interventional cae erie. Method Medical record of 11 eye of 10 patient who underwent intravitreal bevacizumab injection for peritent DME were reviewed. Thi retropective tudy included eye that had peritent DME depite prior par plana vitrectomy with internal limiting membrane removal at our intitution with optical coherence tomography (OCT) aement of DME. All eye received three intravitreal injection of bevacizumab 1.25 mg/0.05 ml monthly. Reult Mean FT wa 408 ± 77 μm at baeline, 453 ± 97 μm at three month, and 454 ± 101 μm at ix month (P = .172). Mean Early Treatment Diabetic Retinopathy tudy (ETDR) letter core were 59 ± 15 (20/80) at baeline, 59 ± 16 (20/80) at three month, 57 ± 15 (20/80) at ix month (P = .398). Concluion No change in VA and FT wa oberved in the hort-term after intravitreal bevacizumab for DME in previouly vitrectomized eye.